1027 related articles for article (PubMed ID: 31386903)
1. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
[TBL] [Abstract][Full Text] [Related]
2. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
5. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.
Bashey A; Zhang X; Jackson K; Brown S; Ridgeway M; Solh M; Morris LE; Holland HK; Solomon SR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):125-33. PubMed ID: 26359881
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Kanate AS; Mussetti A; Kharfan-Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A; Chhabra S; Fenske TS; Freytes C; Gale RP; Ganguly S; Hertzberg M; Klyuchnikov E; Lazarus HM; Olsson R; Perales MA; Rezvani A; Riches M; Saad A; Slavin S; Smith SM; Sureda A; Yared J; Ciurea S; Armand P; Salit R; Bolaños-Meade J; Hamadani M
Blood; 2016 Feb; 127(7):938-47. PubMed ID: 26670632
[TBL] [Abstract][Full Text] [Related]
8. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
[TBL] [Abstract][Full Text] [Related]
9. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
12. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
[TBL] [Abstract][Full Text] [Related]
13. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
14. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
[TBL] [Abstract][Full Text] [Related]
15. Partially CD3
Seif AE; Li Y; Monos DS; Heidemann SC; Aplenc R; Barrett DM; Casper JT; Freedman JL; Grupp SA; Margolis DA; Olson TS; Teachey DT; Keever-Taylor CA; Wang Y; Talano JM; Bunin NJ
Biol Blood Marrow Transplant; 2020 Mar; 26(3):493-501. PubMed ID: 31765697
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
[TBL] [Abstract][Full Text] [Related]
17. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
18. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; Kwon M; Pascual-Cascón MJ; Ferrà C; Sanz J; Gallardo-Morillo A; García-Sola A; Torrent A; Jiménez-Lorenzo MJ; Piñana JL; Montoro J; Oarbeascoa G; Dorado N; Gómez-Centurión I; Muñoz C; Martínez-Laperche C; Anguita J; Buño I; Díez-Martín JL;
Ann Hematol; 2021 Feb; 100(2):541-553. PubMed ID: 33140137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]